Acne Treatment CLARO New At Home Intense Pulse Light Acne Device
CLRS Technology today announced a series of corporate milestones in anticipation of FDA clearance for CLARO, the company’s innovative at-home acne treatment device. Key
business developments include the appointment of a senior marketing executive, expansion of the Board of Directors, commencement of clinical studies and receipt of a design patent.
“It’s an incredibly exciting time at CLRS Technology as we put all the pieces in place to succeed in bringing our flagship product launch to life,” said Richard Oberreiter, CEO and Founder, CLRS Technology. “As we await FDA clearance for CLARO, we are energized by the level of interest and support from the financial and medical community. We have the right team in place to make CLARO a success within one of the fastest growing categories of the aesthetic industry.”
CLRS Technology is poised to enter the $255 million home device category with CLARO, a hand-held Intense Pulse Light (IPL) system based on the same technology used by dermatologists for decades. This flagship product will be the first in a series of hand-held tools designed to provide professional-based solutions for common skin and allergy
conditions. According to Medical Insight Inc, the category is expected to grow to $1 billion in retail sales by 2012 with major corporations setting the pace, including Palomar with Gillette, Syneron and Procter & Gamble, and Light BioScience with L’Oreal.
“We see tremendous opportunity entering this market with a unique acne treatment device that fulfills a consumer need for science-based technology that’s safe, convenient and effective,” said Mr. James Kraushaar, Chairman & Founder, CLRS Technology, whose extensive 15+ years of experience marketing and selling medical IPL systems and aesthetic lasers fueled the development of CLARO. “Chronic acne can damage self-esteem in teens and adults, and current solutions fall short in providing immediate relief. We
believe CLARO will improve the quality of life for sufferers of mild to moderate acne.”
According to Mr. Oberreiter, FDA-clearance for CLARO is anticipated this summer and prescription sales are expected to start in August at dermatologists and family practitioners.
This month also marked the beginning of clinical study for the CLARO under the leadership of Dr. Ronald Moy, Former Co-Chief of the Department of Dermatology and Chief of Dermatologic Surgery, UCLA. The study is designed to evaluate CLARO’s efficacy in resolving acne lesions at 24, 48 and 120 hours.
“I am impressed with the science behind CLARO and anticipate it will perform well in our clinical study,” said Dr. Moy. “Acne is one of the most difficult chronic conditions to treat and I believe that CLARO will offer a valuable at-home solution for teenagers and adults of all ages who want fast results in treating their acne. CLARO will also enable me to provide
better outcomes for my patients by supplementing the care I can provide in-office.”
Also this month, CLRS Technology was awarded a design patent for CLARO, a welcome advantage in the highly competitive marketplace. The patent covers unique components of the CLARO’s industrial design and ergonomic features. CLRS Technology also has multiple pending patents relating to its technology platform that is capable of delivering dermatologist quality results in a home environment.
Related Posts:
If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.
Comments
No comments yet.
Leave a comment